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| INTRODUC TI ON
Liver cirrhosis is an increasingly common disease with high complication rates. It leads to reduced quality of life and a high burden of disease for patients, their family and the healthcare system. 1
Cirrhosis is associated with changes in the structure and functionality of the microbiome of the gut 2-5 and other body sites, such as skin or the mouth. 6 Compared to healthy individuals, a decrease in faecal microbial diversity and an imbalance between commensal and pathogenic taxa is seen in patients with cirrhosis. Furthermore, cirrhosis-associated dysbiosis goes hand in hand with increased gut permeability, intestinal bacterial translocation, intestinal and systemic inflammation leading to complications of cirrhosis and an increased mortality. 3,7-11 Dysbiosis in general and especially in cirrhosis may be caused by host and environmental factors, which shape the microbiome. These factors include alcohol consumption, aetiology and severity of liver disease, diet composition and medication. 5, [12] [13] [14] [15] [16] [17] [18] Drug intake has emerged as one of the most important drivers of dysbiosis. It has recently been shown in vitro that, apart from classic antimicrobials, many other drugs have an extensive impact on human gut bacteria. 19 A population-based deep sequencing study of the faecal microbiome revealed that proton pump inhibitors (PPI) were associated with the most profound microbiome changes, followed by statins, antibiotics, laxatives and beta blockers. 20 Nearly 50% of older adults take one or more medications that are not medically indicated and 45% of patients over the age of 75 take five or more drugs per day. 21 The known consequences of polypharmacy and over-medication are increased healthcare costs, adverse drug reactions, increased rates of drug-drug interactions, decreased performance status of the patients, cognitive impairment, higher risk of falls and non-compliance. Interventions to reduce polypharmacy are difficult to implement. 22, 23 From the currently available data it is not known which of the above described factors may have the strongest impact on faecal microbiome composition in cirrhosis and would therefore be the most promising therapeutic goal.
We therefore conducted a systems biology analysis on a large dataset of cirrhotic patients of different aetiology and disease severity to analyse, which factors have the strongest influence on faecal microbiome composition and predicted metagenomics in patients with liver cirrhosis.
| MATERIAL S AND ME THODS

| Patients
We included faecal 16S microbiome sequencing data from cirrhotic patients recruited at the outpatient clinic of the
Department of Gastroenterology and Hepatology, University
Hospital of Graz, Austria who were screened for an intervention study 10 between July 2012 and September 2013 in this post-hoc analysis. All patients gave written informed consent. Diagnosis of cirrhosis was based on liver histopathological examinations, or a combination of clinical, radiological and/or labouratory features. Patients with a Child-Pugh score of 12 or higher, alcohol consumption within 2 weeks prior to inclusion, active infection at screening, gastrointestinal haemorrhage within 2 weeks prior to inclusion, immuno-modulating drugs, hepatic encephalopathy stage two or higher, renal failure (creatinine over 1.7 mg/ dL), other severe diseases unrelated to cirrhosis, malignancy or pregnancy were excluded. Stool and blood samples analysed in this study were taken before patients received any study medication. The study protocol was approved by the institutional review board (ethics committee) in Graz (23-096 ex 10/11), registered at clinicaltrials.gov (NCT01607528) and performed according to the declaration of Helsinki. The following characteristics were as- 
| Total DNA isolation, 16S library preparation, sequencing and analysis
Total DNA was isolated from frozen stool samples using MagnaPure LC DNA Isolation Kit III (Bacteria, Fungi) (Roche, Mannheim, Germany) according to manufacturer's instructions including mechanic and enzymatic lysis as described in Klymiuk et al 2017. 26 For 16S rDNA sequencing hypervariable regions V1-V2 were amplified in a target-specific PCR (primers: 27F-AGAGTTTGATCCTGGCTCAG; R357-CTGCTGCCTYCCGTA) and amplification products were sequenced after indexing and purification on an Illumina MiSeq desktop sequencer (Illumina, Eindhoven, the Netherlands) according to published procedures. 26, 27 
| Statistical analysis
For microbiome analysis, demultipexed FASTQ files were processed using Qiime2 tools implemented in Galaxy (https ://galaxy. medun igraz.at). Denoising (removing primers, quality filtering, correcting errors in marginal sequences, removing chimeric sequences, removing singletons, joining paired-end reads and dereplication) were done with DADA2. 28 Score matching was performed without replacement based on logistic regression, using R 3.6.1 33 package "MatchIt." 34, 35 The web-based software Calypso version 7.14 (http://cgeno me.net/ calyp so/) was used for analyses of microbiome data. 36 For nonmicrobiome analyses SPSS V25.0.0.1 (IBM, Armonk, NY, USA) was used (descriptive statistics, group comparisions, Spearman Rho correlation, Collinearity analysis) Visualization was performed in R 3.6.1 33 package "ggplot2". 37 Sequencing data have been made publically available at the NCBI Sequence Read Archive (accession number PRJNA390475). A formal samples size calculation was not performed.
| Labouratory measurements
Albumin, bilirubin, hemoglobin, uric acid, creatinine, prothrombin time and CRP were measured in the routine labouratory. LPS was detected in serum with an adapted protocol using HEK-Blue hTLR4 reporter cells (Invivogen, Toulouse, France) as published previously. 38 All other assays were handled according to manufacturers' instructions. Enzyme linked immunosorbent assay were used to measure calprotectin, zonulin and serum DAO (Immundiagnostic AG, Bensheim, Germany), as well as LBP and sCD14 (Hycult biotechnology, Uden, the Netherlands). sCD163 and sMR in plasma samples were measured by an in-house sandwich ELISA using a BEP-2000 ELISA-analyser (Dade Behring) as previously described. 10, 39, 40 Cytokines (interleukin-6, interleukin-8, interleukin-10, TNFalpha) were measured with ProcartaPlex (eBioscience, Vienna, Austria). Neutrophil oxidative burst was measured by flow cytometry using a commercially available kit (Glycotope, Heidelberg, Germany).
| RE SULTS
| Study cohort
Microbiome sequence data of 88 cirrhotic patients were analysed.
Patient characteristics are presented in Table 1 . We analysed the impact of age, sex, smoking status, aetiology of cirrhosis, severity of liver disease, comorbidities, nutritional status, drug intake, intestinal permeability, intestinal and systemic inflammation on faecal microbiome composition. Drug classes that were taken by more than 15% of the study population were included with the exception of lactulose, which was used by only 11% of the study population but was included into univariate analysis due to its supposed microbiome modulating properties. Antibiotics (chinolons) for prophylaxis of spontaneous bacterial peritonitis were only taken by 2 out of 88 patients and rifaximin was not taken by any patients.
Moderate malnutrition was more frequent in hepatitis C cirrhosis (43.8%) compared to alcoholic cirrhosis (19.1%) or other aetilologies (4%, P = .006). No other significant differences between categorical variables were found. Spearman correlation showed a weak, but significant correlation between CRP and disease severity (Spearman Rho r = 0.380, P < .001). No significant correlation between other variables was found. Testing for collinearity showed that all combinations of explanatory variables had a VIF <1.5, excluding a strong codependence.
TA B L E 1 Patient characteristics
| Differences in microbiome composition between groups (beta diversity)
Univariate RDA revealed that severity of liver disease (assessed by Child-Pugh and MELD score), aetiology, PPI use, lactulose use, nu- 
| Species diversity (alpha diversity) and taxonomic differences
We analysed differences in alpha diversity and taxonomic composition in relation to the six variables (severity of disease, aetiology, PPI use, nutritional status, age and CRP) that significantly affected beta diversity of the stool microbiome composition.
For alpha diversity analyses the feature 
| Machine learning and network analysis
To further understand the association of microbiome composition with the factors that were identified to significantly influence beta Figure 5D ) No genera were identified with LASSO to be associated with age or CRP levels.
To visualize the relation of these significant influencing factors we performed a network analysis. Network analysis including severity, PPI use and aetiology as explanatory variables showed some overlaps but also some distinct genera that were only asso- propensity score matching, disease severity, aetiology, PPI use and age were still significant explanatory variables of microbiome composition on multivariate RDA whereas CRP and nutritional status did not influence microbiome composition significantly any more (see Figure S1 ).
Feature selection by LEfSe in the propensity score matched cohort showed comparable results as obtained from the original, non-matched dataset, indicating that the microbiome effects are true effects and not caused by other confounders (see Figure S2 ). To confirm the influence of PPI use independent of severity of liver disease, we additionally per- 
| D ISCUSS I ON
Faecal microbiome composition has been associated with various diseases, but not only disease severity and comorbidities, but also other factors such as medication, diet or lifestyle habits may influence its composition. It is therefore important to discern the effect of different influencing variables as a first step from association to causality. We performed a system biology analysis of a well-characterized cohort of patients with liver cirrhosis and were able to show by multivariate RDA that severity and aetiology of drug intake is missing in both studies, leading to scientific discussions and the need for further reserach 43, 44 In subsequent studies strong associations of microbiome changes with hepatic encephalopathy were shown. 8, 45 Our analysis demonstrates that disease severity, Cirrhosis is a complex disease requiring long-term drug treatment with several drug classes. Many medically approved drugs influence microbiome composition. 19 In liver cirrhosis, PPI use has been described to alter microbiome composition, increase the rate of complications and negatively impact prognosis. 5, [46] [47] [48] [49] We recently expanded this knowledge by describing the consequences of PPI-induced dysbiosis and oralization of the faecal microbiome on inflammation, intestinal permeability and outcome in cirrhosis. 11 In the present study PPI use also had a strong impact on the faecal microbiome, being associated with an increased abundance of oral bacteria and potential pathogens, such as Streptococcus species and Veillonella. Although PPI use and disease severity were partially linked in our cohort, both were still independent factors influencing microbiome composition in subgroup analyses, however low sample size in this analysis weakens the explanatory power.
Also other drugs commonly administered in cirrhosis, may impact the faecal microbiome. However, in our cohort, other drugs influenced microbiome composition to a lesser extent. We were interested in the effect of lactulose on the cirrhotic microbiome, since available data are conflicting, showing no major alterations of the faecal microbiome between lactulose user and non-user, but withdrawal of lactulose leads to the loss of beneficial species. 16, 50, 51 In our cohort only 11% of the cirrhotic patients used lactulose. On univariate analysis we found that lactulose had a weak, but significant, effect on microbiome composition, which did not remain significant in multivariate analysis. Therefore our data support the notion that lactulose has no major effect on the taxonomic composition of the faecal microbiome in cirrhosis and may therefore exert its function through functional microbiome changes. Other drug classes did not have a major impact on microbiome composition.
Liver cirrhosis is also a heterogeneous disease from an aetiological perspective. Aetiology of liver disease as a factor to explain differences in microbiome composition has already been studied. Bajaj et al describe alcohol and non-alcoholic steatohepatitis driven changes in microbiome composition. 45 Hepatitis C alters faecal microbiome which has been implicated in the pathogenesis of HCV-induced chronic liver disease. However, Hepatitis C induced dysbiosis seems to be stable over different disease stages. 52 Chronic cholestatic diseases such as primary biliary and primary sclerosing cholangitis are also associated with distinct changes in microbiome composition. 53 Although aetiology of liver disease was identified as a significant factor by multivariate RDA in our data set, the taxonomic differences of the microbiomes from different aetiologies were surprisingly small in our cohort.
Patients with alcoholic cirrhosis had a higher abundance of the genus Erysipelatoclostridium and the group of patients with "other" aetiologies of liver cirrhosis had a higher abundance of two yet uncultured bacteria of the family Lachnospiraceae and of the genus Blautia. Since liver cirrhosis aetiology is varying in different geographical regions 54 and geographical region itself is a factor that impacts diversity and composition of the microbiome, 55 also the origin of the study population has to be taken into account. Our patient cohort consists only of Caucasians living in the same region, which is a likely explanation for the relatively similar microbiome composition in different aetiologies. Bajaj et al have shown that cirrhotic patients from Turkey, compared to patients from the USA, differ in aetiology and dietary habits, which resulted in a higher microbial diversity in Turkish cirrhotic patients. 14 However, none of these have been previously described to be associated with age related changes in microbiome composition.
Collinsella aerofaciens has been associated with diet and intestinal inflammatory diseases, [58] [59] [60] Slackia with equol production, 61 whereas Alistipes onderdonkii has not been associated with any
human condition yet. 62 Nutritional status is an important prognostic factor in liver cirrhosis. Especially sarcopenia is a frequent complication of malnutrition in cirrhosis and is associated with adverse outcome. 63, 64 Assessing nutritional status in cirrhosis can be challenging. We used the well-established SGA, that is also recommended by the European Association for the Study of the Liver 65 to differentiate between well nourished and moderately malnourished patients. In our cohort of mostly compensated cirrhotic patients we did not have any severely malnourished patients. We found a higher abundance of the order Campylobacterales in moderately malnourished cirrhotics. Campylobacterales have been associated with malnutrition in children. 66, 67 The order Verrucomicrobiales was enriched in adequately nourished cirrhotic patients. So far only one species of this order has been described in human faeces: Akkermansia muciniphila.
A loss of Akkermansia muciniphila has been associated with metabolic diseases and the abundance may be influenced by diet. 68 Changes in microbiome composition in cirrhosis impact intestinal barrier function and lead to intestinal and systemic inflammation due to translocation of bacterial products to the liver and also to the systemic circulation. This concept of a crosstalk between gut, liver and immune system -the so called gut-liver axis-is widely implicated in the pathogenesis of liver disease and a promising therapeutic target. 69, 70 We assessed a panel of biomarkers of the gut-liver axis in our cohort and CRP as a marker of inflammation was found to be a significantly explanatory variable in the multivariate analysis, however the consistency of the effect remains unclear in our dataset. CRP is a well-known biomarker in liver cirrhosis and is predictive for complications and outcome. 71, 72 Increased abundance of Veillonella and Streptococcus species but also Faecalibacterium species were associated with higher CRP levels. While the former support the link between microbiome composition and inflammation in liver cirrhosis, Faecalibacterium species are usually associated with anti-inflammatory properties, making a firm conclusion difficult.
Interestingly, gender did not impact on microbiome composition in our study. In studies in obese individuals, gender seems to cause taxonomic differences, whereas data on changes on alpha and beta diversity are still conflicting. 73, 74 In liver cirrhosis, gender differences have not been associated with changes in beta diversity so far. The male predominance in liver cirrhosis may be a reason for difficulties to detect consistent gender differences.
In summary our cross sectional system biology study shows that disease severity and PPI use are the main factors explaining variation of the faecal microbiome in cirrhosis. Aetiology of liver disease, age, nutritional status and inflammation (CRP levels) are further explanatory variables. The limitation of our study is the single-center design that does not allow to account for geographical differences in the microbiome composition, the cross sectional design that does not allow to draw any conclusions on causality as well as the low sample size in the subgroup analyses. The strength of our study is the thorough characterization of our study patients, that allows detailed analysis of influencing variables. For future studies, we strongly suggest to increase sample size and expand the minimal set of metadata as suggested by the IHMS consortium 75 to include detailed information on disease aetiology, disease severity, drug intake and also information on further essential biomarkers, depending on the disease studied. This will open up new paths to understand the crosstalk between the faecal microbiome and the human body in disease states.
| Lay summary
The composition of gut bacteria-the gut microbiome-is altered in many diseases. In chronic liver diseases, such as liver cirrhosis, the gut microbiome is severely disturbed. We were able to show in this study which factors explain this disturbed microbiome composition.
These factors were: The cause of liver disease, the severity of liver disease, intake of acid-blockers (proton pump inhibitors), age and inflammation. Our study also shows the importance of collecting sufficient data on the disease and drug intake to be able to assess the effects of different factors on the gut microbiome. 
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